Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In Silico Study of Correlation between Missense Variations of <italic>F8</italic> Gene and Inhibitor Formation in Severe Hemophilia A</title><author><name sortKey="Fodil, Mostefa" sort="Fodil, Mostefa" uniqKey="Fodil M" first="Mostefa" last="Fodil">Mostefa Fodil</name><affiliation><nlm:aff id="A1">Higher School of Biological Sciences of Oran (ESSBO), Oran, Algeria</nlm:aff></affiliation></author><author><name sortKey="Zemani, Faouzia" sort="Zemani, Faouzia" uniqKey="Zemani F" first="Faouzia" last="Zemani">Faouzia Zemani</name><affiliation><nlm:aff id="A2">Molecular and Cellular Genetics Laboratory, Oran University of Science and Technology - Mohamed Boudiaf (USTOMB), Oran, Algeria</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31876401</idno><idno type="pmc">7236410</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236410</idno><idno type="RBID">PMC:7236410</idno><idno type="doi">10.4274/tjh.galenos.2019.2019.0094</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000287</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000287</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">In Silico Study of Correlation between Missense Variations of <italic>F8</italic> Gene and Inhibitor Formation in Severe Hemophilia A</title><author><name sortKey="Fodil, Mostefa" sort="Fodil, Mostefa" uniqKey="Fodil M" first="Mostefa" last="Fodil">Mostefa Fodil</name><affiliation><nlm:aff id="A1">Higher School of Biological Sciences of Oran (ESSBO), Oran, Algeria</nlm:aff></affiliation></author><author><name sortKey="Zemani, Faouzia" sort="Zemani, Faouzia" uniqKey="Zemani F" first="Faouzia" last="Zemani">Faouzia Zemani</name><affiliation><nlm:aff id="A2">Molecular and Cellular Genetics Laboratory, Oran University of Science and Technology - Mohamed Boudiaf (USTOMB), Oran, Algeria</nlm:aff></affiliation></author></analytic><series><title level="j">Turkish Journal of Hematology</title><idno type="ISSN">1300-7777</idno><idno type="eISSN">1308-5263</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective:</title><p>Deleterious substitutions of the <italic>F8</italic> gene are responsible for causing hemophilia A, which is an inherited bleeding disorder resulting from reduced or absent activity of the coagulant protein factor VIII (FVIII). The most important complication in treatment is inhibitor development toward therapeutic factor VIII. In this study, we aimed to analyze the effects of deleterious substitutions in the <italic>F8</italic> gene upon protein structure and function.</p></sec><sec><title>Materials and Methods:</title><p>All tests were conducted by computational methods from the CHAMP (CDC Hemophilia A Mutation Project) database. We performed an in silico analysis of deleterious variations using five software programs, Sift, PolyPhen-2, Align-GVGD, KD4v, and MutationTaster, in order to analyze the correlation between variation and the disease. We also studied the correlation between these variations and inhibitor formation.</p></sec><sec><title>Results:</title><p>Our analysis showed that these in silico tools are coherent and that there are more variations in the A than the C domains. Moreover, we noticed that there are more deleterious variations than neutral variations in each of the A and C domains. We also found that 13.51% of the patients suffered from a severe form of hemophilia A and that carriers of missense variations developed inhibitors. Also, for the first time, we determined that variation nature is not associated with inhibitor formation. Furthermore, this analysis showed that the risk of developing inhibitors increases when the variation causes a change of amino acid class.</p></sec><sec><title>Conclusion:</title><p>This study will help to correctly associate variations with inhibitor development and aid in early characterization of novel variants.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Lenting, Pj" uniqKey="Lenting P">PJ Lenting</name></author><author><name sortKey="Van Mourik, Ja" uniqKey="Van Mourik J">JA van Mourik</name></author><author><name sortKey="Mertens, K" uniqKey="Mertens K">K Mertens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="White Gc, 2nd" uniqKey="White Gc 2">2nd White GC</name></author><author><name sortKey="Rosendaal, F" uniqKey="Rosendaal F">F Rosendaal</name></author><author><name sortKey="Aledort, Lm" uniqKey="Aledort L">LM Aledort</name></author><author><name sortKey="Lusher, Jm" uniqKey="Lusher J">JM Lusher</name></author><author><name sortKey="Rothschild, C" uniqKey="Rothschild C">C Rothschild</name></author><author><name sortKey="Ingerslev, J" uniqKey="Ingerslev J">J; Ingerslev</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Viel, Kr" uniqKey="Viel K">KR Viel</name></author><author><name sortKey="Ameri, A" uniqKey="Ameri A">A Ameri</name></author><author><name sortKey="Abshire, Tc" uniqKey="Abshire T">TC Abshire</name></author><author><name sortKey="Iyer, Rv" uniqKey="Iyer R">RV Iyer</name></author><author><name sortKey="Watts, Rg" uniqKey="Watts R">RG Watts</name></author><author><name sortKey="Lutcher, C" uniqKey="Lutcher C">C Lutcher</name></author><author><name sortKey="Channell, C" uniqKey="Channell C">C Channell</name></author><author><name sortKey="Cole, Sa" uniqKey="Cole S">SA Cole</name></author><author><name sortKey="Fernstrom, Km" uniqKey="Fernstrom K">KM Fernstrom</name></author><author><name sortKey="Nakaya, S" uniqKey="Nakaya S">S Nakaya</name></author><author><name sortKey="Kasper, Ck" uniqKey="Kasper C">CK Kasper</name></author><author><name sortKey="Thompson, Ar" uniqKey="Thompson A">AR Thompson</name></author><author><name sortKey="Almasy, L" uniqKey="Almasy L">L Almasy</name></author><author><name sortKey="Howard, Te" uniqKey="Howard T">TE Howard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mannucci, Pm" uniqKey="Mannucci P">PM Mannucci</name></author><author><name sortKey="Tuddenham, Eg" uniqKey="Tuddenham E">EG Tuddenham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fulcher, Ca" uniqKey="Fulcher C">CA Fulcher</name></author><author><name sortKey="De Graaf Mahoney, S" uniqKey="De Graaf Mahoney S">S de Graaf Mahoney</name></author><author><name sortKey="Zimmerman, Ts" uniqKey="Zimmerman T">TS Zimmerman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoyer, Lw" uniqKey="Hoyer L">LW Hoyer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oldenburg, J" uniqKey="Oldenburg J">J Oldenburg</name></author><author><name sortKey="Pavlova, A" uniqKey="Pavlova A">A Pavlova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Witmer, C" uniqKey="Witmer C">C Witmer</name></author><author><name sortKey="Young, G" uniqKey="Young G">G Young</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bardi, E" uniqKey="Bardi E">E Bardi</name></author><author><name sortKey="Astermark, J" uniqKey="Astermark J">J Astermark</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Carcao, M" uniqKey="Carcao M">M Carcao</name></author><author><name sortKey="Re, W" uniqKey="Re W">W Re</name></author><author><name sortKey="Ewenstein, B" uniqKey="Ewenstein B">B Ewenstein</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gorski, Mm" uniqKey="Gorski M">MM Gorski</name></author><author><name sortKey="Blighe, K" uniqKey="Blighe K">K Blighe</name></author><author><name sortKey="Lotta, La" uniqKey="Lotta L">LA Lotta</name></author><author><name sortKey="Pappalardo, E" uniqKey="Pappalardo E">E Pappalardo</name></author><author><name sortKey="Garagiola, I" uniqKey="Garagiola I">I Garagiola</name></author><author><name sortKey="Mancini, I" uniqKey="Mancini I">I Mancini</name></author><author><name sortKey="Mancuso, Me" uniqKey="Mancuso M">ME Mancuso</name></author><author><name sortKey="Fasulo, Mr" uniqKey="Fasulo M">MR Fasulo</name></author><author><name sortKey="Santagostino, E" uniqKey="Santagostino E">E Santagostino</name></author><author><name sortKey="Peyvandi, F" uniqKey="Peyvandi F">F Peyvandi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rosendaal, Fr" uniqKey="Rosendaal F">FR Rosendaal</name></author><author><name sortKey="Palla, R" uniqKey="Palla R">R Palla</name></author><author><name sortKey="Garagiola, I" uniqKey="Garagiola I">I Garagiola</name></author><author><name sortKey="Mannucci, Pm" uniqKey="Mannucci P">PM Mannucci</name></author><author><name sortKey="Peyvandi, F" uniqKey="Peyvandi F">F; Peyvandi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gouw, Sc" uniqKey="Gouw S">SC Gouw</name></author><author><name sortKey="Van Den Berg, Hm" uniqKey="Van Den Berg H">HM van den Berg</name></author><author><name sortKey="Oldenburg, J" uniqKey="Oldenburg J">J Oldenburg</name></author><author><name sortKey="Astermark, J" uniqKey="Astermark J">J Astermark</name></author><author><name sortKey="De Groot, Pg" uniqKey="De Groot P">PG de Groot</name></author><author><name sortKey="Margaglione, M" uniqKey="Margaglione M">M Margaglione</name></author><author><name sortKey="Thompson, Ar" uniqKey="Thompson A">AR Thompson</name></author><author><name sortKey="Van Heerde, W" uniqKey="Van Heerde W">W van Heerde</name></author><author><name sortKey="Boekhorst, J" uniqKey="Boekhorst J">J Boekhorst</name></author><author><name sortKey="Miller, Ch" uniqKey="Miller C">CH Miller</name></author><author><name sortKey="Le Cessie, S" uniqKey="Le Cessie S">S le Cessie</name></author><author><name sortKey="Van Der Bom, Jg" uniqKey="Van Der Bom J">JG van der Bom</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Payne, Ab" uniqKey="Payne A">AB Payne</name></author><author><name sortKey="Miller, Ch" uniqKey="Miller C">CH Miller</name></author><author><name sortKey="Kelly, Fm" uniqKey="Kelly F">FM Kelly</name></author><author><name sortKey="Michael Soucie, J" uniqKey="Michael Soucie J">J Michael Soucie</name></author><author><name sortKey="Craig Hooper, W" uniqKey="Craig Hooper W">W Craig Hooper</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chenna, R" uniqKey="Chenna R">R Chenna</name></author><author><name sortKey="Sugawara, H" uniqKey="Sugawara H">H Sugawara</name></author><author><name sortKey="Koike, T" uniqKey="Koike T">T Koike</name></author><author><name sortKey="Lopez, R" uniqKey="Lopez R">R Lopez</name></author><author><name sortKey="Gibson, Tj" uniqKey="Gibson T">TJ Gibson</name></author><author><name sortKey="Higgins, Dg" uniqKey="Higgins D">DG Higgins</name></author><author><name sortKey="Thompson, Jd" uniqKey="Thompson J">JD Thompson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ng, Pc" uniqKey="Ng P">PC Ng</name></author><author><name sortKey="Henikoff, S" uniqKey="Henikoff S">S Henikoff</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sunyaev, S" uniqKey="Sunyaev S">S Sunyaev</name></author><author><name sortKey="Ramensky, V" uniqKey="Ramensky V">V Ramensky</name></author><author><name sortKey="Bork, P" uniqKey="Bork P">P Bork</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tavtigian, Sv" uniqKey="Tavtigian S">SV Tavtigian</name></author><author><name sortKey="Byrnes, Gb" uniqKey="Byrnes G">GB Byrnes</name></author><author><name sortKey="Goldgar, De" uniqKey="Goldgar D">DE Goldgar</name></author><author><name sortKey="Thomas, A" uniqKey="Thomas A">A Thomas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Luu, Td" uniqKey="Luu T">TD Luu</name></author><author><name sortKey="Rusu, A" uniqKey="Rusu A">A Rusu</name></author><author><name sortKey="Walter, V" uniqKey="Walter V">V Walter</name></author><author><name sortKey="Linard, B" uniqKey="Linard B">B Linard</name></author><author><name sortKey="Poidevin, L" uniqKey="Poidevin L">L Poidevin</name></author><author><name sortKey="Ripp, R" uniqKey="Ripp R">R Ripp</name></author><author><name sortKey="Moulinier, L" uniqKey="Moulinier L">L Moulinier</name></author><author><name sortKey="Muller, J" uniqKey="Muller J">J Muller</name></author><author><name sortKey="Raffelsberger, W" uniqKey="Raffelsberger W">W Raffelsberger</name></author><author><name sortKey="Wicker, N" uniqKey="Wicker N">N Wicker</name></author><author><name sortKey="Lecompte, O" uniqKey="Lecompte O">O Lecompte</name></author><author><name sortKey="Thompson, Jd" uniqKey="Thompson J">JD Thompson</name></author><author><name sortKey="Poch, O" uniqKey="Poch O">O Poch</name></author><author><name sortKey="Nguyen, H" uniqKey="Nguyen H">H Nguyen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwarz, Jm" uniqKey="Schwarz J">JM Schwarz</name></author><author><name sortKey="Rodelsperger, C" uniqKey="Rodelsperger C">C Rödelsperger</name></author><author><name sortKey="Schuelke, M" uniqKey="Schuelke M">M Schuelke</name></author><author><name sortKey="Seelow, D" uniqKey="Seelow D">D Seelow</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamasaki Katagiri, N" uniqKey="Hamasaki Katagiri N">N Hamasaki-Katagiri</name></author><author><name sortKey="Salari, R" uniqKey="Salari R">R Salari</name></author><author><name sortKey="Wu, A" uniqKey="Wu A">A Wu</name></author><author><name sortKey="Qi, Y" uniqKey="Qi Y">Y Qi</name></author><author><name sortKey="Schiller, T" uniqKey="Schiller T">T Schiller</name></author><author><name sortKey="Filiberto, Ac" uniqKey="Filiberto A">AC Filiberto</name></author><author><name sortKey="Schisterman, Ef" uniqKey="Schisterman E">EF Schisterman</name></author><author><name sortKey="Komar, Aa" uniqKey="Komar A">AA Komar</name></author><author><name sortKey="Przytycka, Tm" uniqKey="Przytycka T">TM Przytycka</name></author><author><name sortKey="Kimchi Sarfaty, C" uniqKey="Kimchi Sarfaty C">C Kimchi-Sarfaty</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Doss, Cgp" uniqKey="Doss C">CGP Doss</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu, Ml" uniqKey="Liu M">ML Liu</name></author><author><name sortKey="Shen, Bw" uniqKey="Shen B">BW Shen</name></author><author><name sortKey="Nakaya, S" uniqKey="Nakaya S">S Nakaya</name></author><author><name sortKey="Pratt, Kp" uniqKey="Pratt K">KP Pratt</name></author><author><name sortKey="Fujikawa, K" uniqKey="Fujikawa K">K Fujikawa</name></author><author><name sortKey="Davie, Ew" uniqKey="Davie E">EW Davie</name></author><author><name sortKey="Stoddard, Bl" uniqKey="Stoddard B">BL Stoddard</name></author><author><name sortKey="Thompson, Ar" uniqKey="Thompson A">AR Thompson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sengupta, M" uniqKey="Sengupta M">M Sengupta</name></author><author><name sortKey="Sarkar, D" uniqKey="Sarkar D">D Sarkar</name></author><author><name sortKey="Ganguly, K" uniqKey="Ganguly K">K Ganguly</name></author><author><name sortKey="Sengupta, D" uniqKey="Sengupta D">D Sengupta</name></author><author><name sortKey="Bhaskar, S" uniqKey="Bhaskar S">S Bhaskar</name></author><author><name sortKey="Ray, K" uniqKey="Ray K">K Ray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bogdanova, N" uniqKey="Bogdanova N">N Bogdanova</name></author><author><name sortKey="Markoff, A" uniqKey="Markoff A">A Markoff</name></author><author><name sortKey="Eisert, R" uniqKey="Eisert R">R Eisert</name></author><author><name sortKey="Wermes, C" uniqKey="Wermes C">C Wermes</name></author><author><name sortKey="Pollmann, H" uniqKey="Pollmann H">H Pollmann</name></author><author><name sortKey="Todorova, A" uniqKey="Todorova A">A Todorova</name></author><author><name sortKey="Chlystun, M" uniqKey="Chlystun M">M Chlystun</name></author><author><name sortKey="Nowak Gottl, U" uniqKey="Nowak Gottl U">U Nowak-Göttl</name></author><author><name sortKey="Horst, J" uniqKey="Horst J">J Horst</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jayandharan, G" uniqKey="Jayandharan G">G Jayandharan</name></author><author><name sortKey="Shaji, Rv" uniqKey="Shaji R">RV Shaji</name></author><author><name sortKey="Baidya, S" uniqKey="Baidya S">S Baidya</name></author><author><name sortKey="Nair, Sc" uniqKey="Nair S">SC Nair</name></author><author><name sortKey="Chandy, M" uniqKey="Chandy M">M Chandy</name></author><author><name sortKey="Srivastava, A" uniqKey="Srivastava A">A Srivastava</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oldenburg, J" uniqKey="Oldenburg J">J Oldenburg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pipe, Sw" uniqKey="Pipe S">SW Pipe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ogata, K" uniqKey="Ogata K">K Ogata</name></author><author><name sortKey="Selvaraj, Sr" uniqKey="Selvaraj S">SR Selvaraj</name></author><author><name sortKey="Miao, Hz" uniqKey="Miao H">HZ Miao</name></author><author><name sortKey="Pipe, Sw" uniqKey="Pipe S">SW Pipe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saenko, El" uniqKey="Saenko E">EL Saenko</name></author><author><name sortKey="Ananyeva, Nm" uniqKey="Ananyeva N">NM Ananyeva</name></author><author><name sortKey="Tuddenham, Egd" uniqKey="Tuddenham E">EGD Tuddenham</name></author><author><name sortKey="Kemball Cook, G" uniqKey="Kemball Cook G">G Kemball-Cook</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thompson, Ar" uniqKey="Thompson A">AR Thompson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pittman, Dd" uniqKey="Pittman D">DD Pittman</name></author><author><name sortKey="Kaufman, Rj" uniqKey="Kaufman R">RJ Kaufman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Butenas, S" uniqKey="Butenas S">S Butenas</name></author><author><name sortKey="Van Veer, C" uniqKey="Van Veer C">C van’t Veer</name></author><author><name sortKey="Mann, Kg" uniqKey="Mann K">KG Mann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcmullen, Ba" uniqKey="Mcmullen B">BA McMullen</name></author><author><name sortKey="Fujikawa, K" uniqKey="Fujikawa K">K Fujikawa</name></author><author><name sortKey="Davie, Ew" uniqKey="Davie E">EW Davie</name></author><author><name sortKey="Hedner, U" uniqKey="Hedner U">U Hedner</name></author><author><name sortKey="Ezban, M" uniqKey="Ezban M">M Ezban</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gouw, Sc" uniqKey="Gouw S">SC Gouw</name></author><author><name sortKey="Van Der Bom, Jg" uniqKey="Van Der Bom J">JG van der Bom</name></author><author><name sortKey="Ljung, R" uniqKey="Ljung R">R Ljung</name></author><author><name sortKey="Escuriola, C" uniqKey="Escuriola C">C Escuriola</name></author><author><name sortKey="Cid, Ar" uniqKey="Cid A">AR Cid</name></author><author><name sortKey="Claeyssens Donadel, S" uniqKey="Claeyssens Donadel S">S Claeyssens-Donadel</name></author><author><name sortKey="Van Geet, C" uniqKey="Van Geet C">C van Geet</name></author><author><name sortKey="Kenet, G" uniqKey="Kenet G">G Kenet</name></author><author><name sortKey="M Kipernaa, A" uniqKey="M Kipernaa A">A Mäkipernaa</name></author><author><name sortKey="Molinari, Ac" uniqKey="Molinari A">AC Molinari</name></author><author><name sortKey="Muntean, W" uniqKey="Muntean W">W Muntean</name></author><author><name sortKey="Kobelt, R" uniqKey="Kobelt R">R Kobelt</name></author><author><name sortKey="Rivard, G" uniqKey="Rivard G">G Rivard</name></author><author><name sortKey="Santagostino, E" uniqKey="Santagostino E">E Santagostino</name></author><author><name sortKey="Thomas, A" uniqKey="Thomas A">A Thomas</name></author><author><name sortKey="Van Den Berg, Hm" uniqKey="Van Den Berg H">HM; van den Berg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spena, S" uniqKey="Spena S">S Spena</name></author><author><name sortKey="Garagiola, I" uniqKey="Garagiola I">I Garagiola</name></author><author><name sortKey="Cannav, A" uniqKey="Cannav A">A Cannavò</name></author><author><name sortKey="Mortarino, M" uniqKey="Mortarino M">M Mortarino</name></author><author><name sortKey="Mannucci, Pm" uniqKey="Mannucci P">PM Mannucci</name></author><author><name sortKey="Rosendaal, Fr" uniqKey="Rosendaal F">FR Rosendaal</name></author><author><name sortKey="Peyvandi, F" uniqKey="Peyvandi F">F; Peyvandi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schwaab, R" uniqKey="Schwaab R">R Schwaab</name></author><author><name sortKey="Pavlova, A" uniqKey="Pavlova A">A Pavlova</name></author><author><name sortKey="Albert, T" uniqKey="Albert T">T Albert</name></author><author><name sortKey="Caspers, M" uniqKey="Caspers M">M Caspers</name></author><author><name sortKey="Oldenburg, J" uniqKey="Oldenburg J">J Oldenburg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chaves, Dg" uniqKey="Chaves D">DG Chaves</name></author><author><name sortKey="Velloso Rodrigues, C" uniqKey="Velloso Rodrigues C">C Velloso-Rodrigues</name></author><author><name sortKey="Moreau, V" uniqKey="Moreau V">V Moreau</name></author><author><name sortKey="Nguyen, C" uniqKey="Nguyen C">C Nguyen</name></author><author><name sortKey="Villard, S" uniqKey="Villard S">S Villard</name></author><author><name sortKey="Belisario, Ar" uniqKey="Belisario A">AR Belisário</name></author><author><name sortKey="Granier, C" uniqKey="Granier C">C Granier</name></author><author><name sortKey="Santoro, Mm" uniqKey="Santoro M">MM Santoro</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Turk J Haematol</journal-id><journal-id journal-id-type="iso-abbrev">Turk J Haematol</journal-id><journal-id journal-id-type="publisher-id">TJH</journal-id><journal-title-group><journal-title>Turkish Journal of Hematology</journal-title></journal-title-group><issn pub-type="ppub">1300-7777</issn><issn pub-type="epub">1308-5263</issn><publisher><publisher-name>Galenos Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31876401</article-id><article-id pub-id-type="pmc">7236410</article-id><article-id pub-id-type="doi">10.4274/tjh.galenos.2019.2019.0094</article-id><article-id pub-id-type="publisher-id">38415</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>In Silico Study of Correlation between Missense Variations of <italic>F8</italic> Gene and Inhibitor Formation in Severe Hemophilia A</article-title><trans-title-group xml:lang="tr"><trans-title>Ağır Hemofili A’da Yanlış Anlamlı <italic>F8</italic> Gen Varyasyonları ile İnhibitör Oluşumu İlişkisini İnceleyen Bilgisayar Simülasyon Çalışması</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fodil</surname><given-names>Mostefa</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref rid="COR1" ref-type="corresp">*</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2856-1988</contrib-id></contrib><contrib contrib-type="author"><name><surname>Zemani</surname><given-names>Faouzia</given-names></name><xref ref-type="aff" rid="A2">2</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1552-4355</contrib-id></contrib></contrib-group><aff id="A1"><label>1</label>Higher School of Biological Sciences of Oran (ESSBO), Oran, Algeria</aff><aff id="A2"><label>2</label>Molecular and Cellular Genetics Laboratory, Oran University of Science and Technology - Mohamed Boudiaf (USTOMB), Oran, Algeria</aff><author-notes><corresp id="COR1">* Address for Correspondence: Higher School of Biological Sciences of Oran (ESSBO), Oran, Algeria Phone: +213699436929 E-mail:<email>mostefa.fodil@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>6</day><month>5</month><year>2020</year></pub-date><volume>37</volume><issue>2</issue><fpage>77</fpage><lpage>83</lpage><history><date date-type="received"><day>5</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>© Copyright 2020 by Turkish Society of Hematology / Turkish Journal of Hematology, Published by Galenos Publishing House.</copyright-statement><copyright-year>2020</copyright-year><license xlink:href="http://creativecommons.org/licenses/by/2.5/" license-type="open-access"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Objective:</title><p>Deleterious substitutions of the <italic>F8</italic> gene are responsible for causing hemophilia A, which is an inherited bleeding disorder resulting from reduced or absent activity of the coagulant protein factor VIII (FVIII). The most important complication in treatment is inhibitor development toward therapeutic factor VIII. In this study, we aimed to analyze the effects of deleterious substitutions in the <italic>F8</italic> gene upon protein structure and function.</p></sec><sec><title>Materials and Methods:</title><p>All tests were conducted by computational methods from the CHAMP (CDC Hemophilia A Mutation Project) database. We performed an in silico analysis of deleterious variations using five software programs, Sift, PolyPhen-2, Align-GVGD, KD4v, and MutationTaster, in order to analyze the correlation between variation and the disease. We also studied the correlation between these variations and inhibitor formation.</p></sec><sec><title>Results:</title><p>Our analysis showed that these in silico tools are coherent and that there are more variations in the A than the C domains. Moreover, we noticed that there are more deleterious variations than neutral variations in each of the A and C domains. We also found that 13.51% of the patients suffered from a severe form of hemophilia A and that carriers of missense variations developed inhibitors. Also, for the first time, we determined that variation nature is not associated with inhibitor formation. Furthermore, this analysis showed that the risk of developing inhibitors increases when the variation causes a change of amino acid class.</p></sec><sec><title>Conclusion:</title><p>This study will help to correctly associate variations with inhibitor development and aid in early characterization of novel variants.</p></sec></abstract><trans-abstract xml:lang="tr"><sec><title>Amaç:</title><p><italic>F8</italic> genindeki patolojik varyasyonlar, pıhtılaşma faktörü VIII’in (FVIII) azalmış ya da kaybolmuş aktivitesinden kaynaklanan ve kalıtsal bir kanama bozukluğu olan Hemofili A’ya neden olmaktadır. Tedavide en önemli zorluk, tedavi edici faktör VIII’e karşı inhibitör gelişimidir. Bu çalışmada <italic>F8</italic> gen varyasyonlarının protein yapısı ve fonksiyonu üzerine olan etkilerini incelemeyi amaçladık.</p></sec><sec><title>Gereç ve Yöntemler:</title><p>Tüm testler CHAMP (CDC Hemofili A Mutasyon Projesi) veri tabanından bilgisayar hesaplama yöntemleriyle yapıldı. Varyasyon ve hastalık arasındaki ilişkiyi araştırmak için beş farklı yazılım programı; Sift, PolyPhen-2, Align-GVGD, KD4v ve MutationTaster kullanarak, patojenik varyasyonların analizi yapıldı. İlave olarak bu varyasyonlar ve inhibitör oluşumu arasındaki ilişki de incelendi.</p></sec><sec><title>Bulgular:</title><p>Analizlerimiz bilgisayar tahmin araçlarının tutarlı olarak A bölgesinde, C bölgesine kıyasla daha fazla varyasyon olduğunu gösterdi. Ayrıca A ve C bölgelerinde nötral varyasyonlardan ziyade patojenik varyasyonlar bulunduğunu fark ettik. Ayrıca hastaların %13,51’inin ağır hemofili A olduğunu ve yanlış anlamlı varyasyon taşıyıcılarının inhibitör geliştirdiğini bulduk. Ayrıca ilk kez varyasyon türünün inhibitör oluşumu ile ilişkili olmadığını gösterdik. İlave olarak bu analiz, aminoasit değişimine yol açan varyasyonların inhibitör geliştirme riskini arttırdığını bize gösterdi.</p></sec><sec><title>Sonuç:</title><p>Bu çalışma inhibitör gelişimi ile varyasyonları doğru bir şekilde ilişkilendirmeye ve yeni varyasyonların erken karakterizasyonuna yardımcı olacaktır.</p></sec></trans-abstract><kwd-group><kwd>Hemophilia A</kwd><kwd>Missense variation</kwd><kwd>In silico analysis</kwd><kwd>Inhibitor formation</kwd><kwd>FVIII</kwd><kwd>Coagulation</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>The X-linked bleeding disorder hemophilia A (HA) (OMIM #306700) is caused by a decrease or dysfunction in circulating blood coagulation factor VIII. This coagulation defect is present in 1/5000 of the male population [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>]. According to the residual plasma FVIII coagulant activity (FVIII: C), HA can be classified into 3 forms: severe (FVIII: C<1%), moderate (1% <xref rid="ref2" ref-type="bibr">2</xref>]. Treatment of hemorrhages in hemophiliac patients consists of protein replacement therapy using plasma-derived or recombinant FVIII [<xref rid="ref3" ref-type="bibr">3</xref>,<xref rid="ref4" ref-type="bibr">4</xref>]. A serious complication of this therapy is the development of inhibitors (i.e. neutralizing alloantibodies against FVIII), which negate treatment benefits [<xref rid="ref2" ref-type="bibr">2</xref>,<xref rid="ref5" ref-type="bibr">5</xref>,<xref rid="ref6" ref-type="bibr">6</xref>]. This process is observed in more than 30% of patients with severe HA. However, only 3% to 13% of patients with moderate and mild HA develop these inhibitors [<xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref8" ref-type="bibr">8</xref>]. Several studies showed that determinants of inhibitor formation include environmental factors [<xref rid="ref9" ref-type="bibr">9</xref>,<xref rid="ref10" ref-type="bibr">10</xref>,<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref12" ref-type="bibr">12</xref>] as well as the patient’s genetic background. The type of variation in the <italic>F8</italic> gene is the strongest risk factor for inhibitor development [<xref rid="ref7" ref-type="bibr">7</xref>,<xref rid="ref13" ref-type="bibr">13</xref>]. A recent meta-analysis confirmed that the risk of patients with large deletions and nonsense variations was higher when compared with the risk of inhibitor development in patients with intron 22 inversion [<xref rid="ref13" ref-type="bibr">13</xref>]. The same study showed that the risk of patients with intron 1 inversions and splice-site variations was equal, and the risk of patients with small deletions and insertions and missense variations was lower [<xref rid="ref13" ref-type="bibr">13</xref>].</p><p>In our study, the role of <italic>F8</italic> missense variations in inhibitor risk was evaluated in a cohort of 407 patients with severe HA extracted from the CDC Hemophilia A Mutation Project (CHAMP) database [<xref rid="ref14" ref-type="bibr">14</xref>]. We have also assessed the impact of these missense variations on the structure and/or function of the FVIII protein using in silico programs.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Extraction of Variation Information</title><p>The variation information of <italic>F8 </italic>was retrieved from the CHAMP database for our analysis [<xref rid="ref14" ref-type="bibr">14</xref>]. Among the 2537 variations listed in the CHAMP database until 2014, we selected 407 missense exon variations from severe hemophilia A patients for this study. Among these variants, 296 have known inhibitor status.</p></sec><sec id="s2b"><title>Evaluation of the Variations</title></sec><sec id="s2c"><title>Clustal W2</title><p>This software uses sequence homology to study the conservation between species during evolution [<xref rid="ref15" ref-type="bibr">15</xref>]. The protein sequences of <italic>Mus musculus, Rattus norvegicus, </italic>and <italic>Macaca fascicularis</italic> were collected from the UniProt database (http://www.uniprot.org/) regarding their phylogenetic proximity. We then aligned these sequences to locate the variations relative to the important regions of the genome that are most conserved.</p></sec><sec id="s2d"><title>SIFT</title><p>Sorting Intolerant From Tolerant (SIFT) is a program based on sequence homology to predict whether an amino acid substitution will affect protein function [<xref rid="ref16" ref-type="bibr">16</xref>]. The scores are classified as intolerant (0.00-0.05), potentially intolerant (0.051-0.10), borderline (0.101-0.20), or tolerant (0.201-1.00). A tolerant substitution does not have deleterious effects on protein function. On the other hand, intolerant substitution appears to have a partial or complete impact on the loss of protein function.</p></sec><sec id="s2e"><title>PolyPhen-2</title><p>Polymorphism Phenotyping v2 (PolyPhen-2), available as software and via a Web server, predicts the possible impact of amino acid substitutions on the stability and function of human proteins using structural and comparative evolutionary considerations [<xref rid="ref17" ref-type="bibr">17</xref>]. It is based on three types of information: the multiple alignment, structural information from the database structure (PDB), and the physicochemical properties of the amino acids. Predictions of a variation’s effect on protein structure are assigned as “probably damaging”, with a score of ≥2.000, and “possibly damaging”, with a score of 1.500-1.999, which means that these variations may affect protein function and/or structure. Finally, “benign”, with a score of 0.000-0.999, signifies no likely phenotypic effect.</p></sec><sec id="s2f"><title>Align-GVGD</title><p>Align-GVGD is a freely available web-based program that combines multiple sequence alignment and biophysical characteristics of amino acids that are based on Grantham distance [<xref rid="ref18" ref-type="bibr">18</xref>]. The Grantham distance calculates the physicochemical difference between two amino acids. If this distance is important, it means that the two amino acids are different. The results are established as classes C0 to C65. Classes C45 to C65 are more likely to affect the function, while classes C0 to C25 are less likely to affect the function.</p></sec><sec id="s2g"><title>KD4v</title><p>KD4v is based on two complementary services: the first is similar to other prediction software such as SIFT and PolyPhen-2, while the second is based on the information and the three-dimensional (3D) structure to predict changes in size, charge, polarity, hydrophobicity, accessibility, and physicochemical properties of amino acids due to a missense variation [<xref rid="ref19" ref-type="bibr">19</xref>]. KD4v predicts whether the variation is “neutral” or “deleterious” for the protein.</p></sec><sec id="s2h"><title>MutationTaster</title><p>MutationTaster is a free web-based application to evaluate DNA sequence variants for their disease-causing potential. The software performs a battery of in silico tests to estimate the impact of the variant on the gene product/protein. This program was designed for the rapid assessment of the potential pathogenic alterations in DNA sequences [<xref rid="ref20" ref-type="bibr">20</xref>]. It integrates information from different databases and biomedical analyses that include conservation during evolution, changes in splice sites, and the loss of protein function. MutationTaster predicts if the variation is “disease-causing” or just a “polymorphism”.</p></sec><sec id="s2i"><title>Statistical Analysis</title><p>In order to evaluate statistical differences between different groups (presence or absence of inhibitors) we used the chi-square test (χ<sup>2</sup>). Classical chi-square evaluation is possible when numbers are greater than 5. An estimated p-value of less than or equal to 0.05 was considered to be statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><p>Among the 407 exon variations studied by ClustalW2, 378 (92.87%) are located in highly conserved regions. We applied five in silico tools, SIFT, PolyPhen-2, Align-GVGD, KD4v, and MutationTaster, to predict the effects of each variation on the protein function and/or structure (<xref rid="t1" ref-type="table">Table 1</xref>).</p><p>For the rest of the analysis, we chose to take into consideration the results of KD4V, since it is a software program based on structure homology and also considers the information on the three-dimensional structure. The results obtained allowed us to classify variations as deleterious or neutral. First, we studied the distribution of variations according to domains A (A1+A2+A3) and C (C1+C2) of the FVIII protein. The variations located on the B domain were not included in this study. In fact, the B domain does not play a major role in blood clotting. Our results showed that the A domain contains four times more variations than the C domain (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>We then examined the distribution of deleterious and neutral variations according to the A and C domains. Therefore, we calculated the frequencies of deleterious and neutral variations in each domain: A1, A2, A3, C1, and C2. We noticed that deleterious variations were significantly more prevalent than neutral variations in each domain (p<0.001) (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>Among the 407 variations, 296 (72.73%) variants have known inhibitor status. Accordingly, 13.51% of patients developed inhibitors, while 86.49% did not (<xref rid="t2" ref-type="table">Table 2</xref>). In order to test the correlation between the nature of the variation (deleterious/neutral) and inhibitor formation, frequencies of deleterious and neutral variations in the two groups of patients were calculated (developing or not developing inhibitors). The results showed the absence of a correlation between inhibitor development and variation nature (<xref ref-type="fig" rid="f3">Figure 3</xref>). In fact, in the group of patients developing inhibitors, there were no statistically differences between deleterious and neutral variations frequencies (13.54% vs. 13.43%; p=0.9). The same results were observed in the second group of patients that did not develop inhibitors (86.46% vs. 86.57%; p=0.9).</p><p>We then studied the impact of the localization of a variation on the A1, A2, A3, C1, and C2 domains on inhibitor formation. Therefore, for each domain we calculated the variant frequencies among the group of patients developing inhibitors. Frequencies of patients with missense variations located in the A3 and C2 domains were higher than those with variations located in the A1, A2, and C1 domains (<xref ref-type="fig" rid="f3">Figure 3</xref>). However, this difference was not statistically significant (p=0.19).</p><p>Finally, we assigned four different classes of amino acids according to the properties of their side chains [class 1: hydrophobic (A, V, F, P, M, I, L, W); class 2: polar uncharged (S, Y, N, Q, C, T, H, G); class 3: acidic (D, E); class 4: basic (K, R)] Then we examined whether substitution caused changes in the amino acid class. The substitution of the wild-type amino acid by an amino acid from the same class gives an intra-class substitution. However, its replacement by an amino acid of another class results in inter-class substitution.</p><p>Comparison of all intra- and inter-amino acid substitutions showed that a significantly greater incidence of inhibitor formation was observed in the case of inter-amino acid substitutions than intra-amino acid substitutions: 28 (70%) vs. 12 (30%) (p=0.003, according to a normal distribution) (<xref rid="t3" ref-type="table">Table 3</xref>).</p></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>Alterations of the <italic>F8</italic> gene are extremely diverse. Many bioinformatics tools were used to assess the impact of these variations on protein function. These are based on the study of sequence conservation, amino acid physicochemical properties, and the information concerning the 3D structure of the FVIII protein [<xref rid="ref21" ref-type="bibr">21</xref>,<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref23" ref-type="bibr">23</xref>]. In this perspective, we analyzed 407 variations extracted from the CHAMP database. We selected exon missense variations that are responsible for the severe form of HA.</p><p>The conservation analysis study focused on the most important regions that can influence the stability, the function, and the structure of the FVIII protein. The results obtained by ClustalW2 showed that 92.87% of the analyzed variations were located in highly conserved regions. Therefore, these variations are likely to have a very important deleterious effect on the function of the FVIII protein [<xref rid="ref24" ref-type="bibr">24</xref>].</p><p>We then studied the distribution of the variations according to the A and C domains. The variations located in the B domain were not included in this study. In fact, the B domain does not play a major role in blood clotting, but it is involved in intra-cellular interactions such as the regulation of quality control and secretion. Therefore, it could be considered that missense variations located in the B domain can only affect the efficiency of secretion of FVIII [<xref rid="ref25" ref-type="bibr">25</xref>,<xref rid="ref26" ref-type="bibr">26</xref>]. Indeed, if a missense variation is identified in the B domain in a patient with HA, it would be necessary to look for other variations in the other domains of the <italic>F8</italic> gene.</p><p>Our results showed that there are four times more variations in the A domains than the C domains (80.34% vs. 19.66%, p<0.001). This is probably due to the fact that the peptide sequences of the A domains (1112 amino acids) are approximately three times longer than the peptide sequences of the C domains (312 amino acids) [<xref rid="ref27" ref-type="bibr">27</xref>,<xref rid="ref28" ref-type="bibr">28</xref>].</p><p>On the other hand, we studied the impact of the 407 variations using five in silico tools, SIFT, PolyPhen-2, Align-GVGD, KD4v, and MutationTaster, in order to predict deleterious and/or damaging effect of variations. The combination of the results obtained by these software programs showed that there were more deleterious than neutral variations. This observation was in keeping with the patients’ phenotypes as they developed the severe form of HA. According to KD4v results, we noticed that there were three times more deleterious variations than neutral variations. This difference was still valid for each of the A domains (A1, A2, and A3) and C domains (C1 and C2) (p<0.001). This observation was in correlation with the results obtained by MutationTaster, which predicted that 87.22% of the variations were disease-causing and 12.78% were polymorphisms. Regarding the neutral variations, they probably represent polymorphisms that are not responsible for the disease. In fact, it has been reported that in 2% to 18% of patients with HA, no genetic alterations were detected except polymorphisms [<xref rid="ref29" ref-type="bibr">29</xref>,<xref rid="ref30" ref-type="bibr">30</xref>,<xref rid="ref31" ref-type="bibr">31</xref>]. Moreover, the A and C domains have important interaction sites. Indeed, the activation sites of the FVIII protein by thrombin are located in the A domain (Arg372, Arg740, and Arg1689) [<xref rid="ref32" ref-type="bibr">32</xref>]. Consequently, if a variation affects one of these sites, the FVIII will not be activated and the tenase complex will not activate the FX. This induces the arrest of the coagulation cascade [<xref rid="ref33" ref-type="bibr">33</xref>]. Furthermore, the C domain interacts with von Willebrand factor and the phospholipid membrane. These interactions are responsible for maintaining the stability and structure of the FVIII protein [<xref rid="ref7" ref-type="bibr">7</xref>]. Besides, the A domain has six disulfide bonds (Cys-Cys) and the C domain contains only two. Those bridges are responsible for the protein stability and risk being broken because of missense variations [<xref rid="ref34" ref-type="bibr">34</xref>].</p><p>Furthermore, in order to study the correlation between the impact of the variations and inhibitor formation, we examined the 296 variations that have known inhibitor status. We have shown that 13.51% of the patients with a severe form of HA carrying missense variations developed inhibitors. This frequency is higher than that found in Oldenburg and Pavlova’s study, where HA patients with missense variations had a risk of 5% of developing inhibitors [<xref rid="ref7" ref-type="bibr">7</xref>]. This difference can be explained by the fact that our study concerns only the severe form of HA. In a recent study, Spena et al. [<xref rid="ref36" ref-type="bibr">36</xref>] evaluated the association between <italic>F8</italic> gene variants and inhibitor development by analyzing 231 causative variants, grouped as low-risk and high-risk variations according to Gouw et al. [<xref rid="ref35" ref-type="bibr">35</xref>]. Only a small difference was observed in the cumulative inhibitor incidence [32.0% (95% CI=18.9 to 45.1) vs. 37.9% (95% CI=29.9 to 45.9)] for low- and high-risk variations classified corresponding to a hazard ratio of 1.35 (95% CI=0.78-2.35) [<xref rid="ref36" ref-type="bibr">36</xref>].</p><p>Otherwise, according to the hypothesis of Schwaab et al. [<xref rid="ref37" ref-type="bibr">37</xref>], the low risk of developing inhibitors in patients with missense variations is due to the fact that patients with missense variations synthesize some endogenous protein that, although functionally altered, are sufficient to induce immune tolerance.</p><p>We supposed that a deleterious variation that alters the protein function and structure might increase the risk of developing inhibitors. We noticed that there were no correlations between deleterious missense variations and inhibitor formation (p=0.9).</p><p>We then studied the association between the location of a variation in the A and C domains with inhibitor formation. We observed that these variations are located in different domains. There were more variations located in the A3 and C2 domains (respectively 20.55% and 18.75%) than the other domains. However, this difference was not significant (p=0.19). Indeed, the FVIII inhibitors recognize epitopes on all the domains [<xref rid="ref38" ref-type="bibr">38</xref>].</p><p>Finally, we analyzed the impact of a change of physicochemical properties of amino acids due to missense variations according to inhibitor formation. Our data showed that the risk of developing inhibitors increases when the variation causes a change of amino acid class (70% vs. 30%; p=0.003). These results support those of Schwaab et al. [<xref rid="ref37" ref-type="bibr">37</xref>] study (91.5%). This percentage decreases (8.5%) in the case of patients with missense variations that do not cause changes in amino acid class [<xref rid="ref37" ref-type="bibr">37</xref>].</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusion</title><p>Our study showed that there are more variations in the A than the C domain. Moreover, we noticed that there are more deleterious than neutral variations in each of the A and C domains. For the first time, we have determined that variation nature is not associated with inhibitor formation. This study showed that variations in patients developing inhibitors are localized on both A and C domains of FVIII. Finally, we showed that the risk of developing inhibitors increases when the variation causes a change of amino acid class.</p><p>This analysis showed that combining information from different tools may facilitate a better understanding for predictive accuracy in determining the functional impact of a given variation.</p></sec></body><back><ack><p>The authors state that they have no interests that might be perceived as posing a conflict or bias.</p></ack><fn-group><fn id="FN1" fn-type="other"><p><bold>Ethics</bold></p><p><bold>Ethics Committee Approval:</bold> Not applicable.</p><p><bold>Informed Consent:</bold> Not applicable.</p></fn><fn id="FN2" fn-type="con"><p><bold>Authorship Contributions</bold></p><p>Concept: M.F., F.Z.; Design: M.F., F.Z.; Analysis or Interpretation: M.F., F.Z.; Writing: M.F., F.Z.</p></fn><fn id="FN3" fn-type="COI-statement"><p><bold>Conflict of Interest:</bold> No conflict of interest was declared by the authors.</p></fn><fn id="FN4" fn-type="financial-disclosure"><p><bold>Financial Disclosure:</bold> The authors declared that this study received no financial support.</p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>1</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Lenting</surname><given-names>PJ</given-names></name><name><surname>van Mourik</surname><given-names>JA</given-names></name><name><surname>Mertens</surname><given-names>K</given-names></name></person-group><article-title>The life cycle of coagulation factor VIII in view of its structure and function</article-title><source>Blood</source><year>1998</year><volume>92</volume><fpage>3983</fpage><lpage>3996</lpage><pub-id pub-id-type="pmid">9834200</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>White GC</surname><given-names>2nd</given-names></name><name><surname>Rosendaal</surname><given-names>F</given-names></name><name><surname>Aledort</surname><given-names>LM</given-names></name><name><surname>Lusher</surname><given-names>JM</given-names></name><name><surname>Rothschild</surname><given-names>C</given-names></name><name><surname>Ingerslev</surname><given-names>J;</given-names></name></person-group><collab>Factor VIII and Factor IX Subcommittee</collab><article-title>Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis</article-title><source>Thromb Haemost</source><year>2001</year><volume>85</volume><fpage>560</fpage><pub-id pub-id-type="pmid">11307831</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Viel</surname><given-names>KR</given-names></name><name><surname>Ameri</surname><given-names>A</given-names></name><name><surname>Abshire</surname><given-names>TC</given-names></name><name><surname>Iyer</surname><given-names>RV</given-names></name><name><surname>Watts</surname><given-names>RG</given-names></name><name><surname>Lutcher</surname><given-names>C</given-names></name><name><surname>Channell</surname><given-names>C</given-names></name><name><surname>Cole</surname><given-names>SA</given-names></name><name><surname>Fernstrom</surname><given-names>KM</given-names></name><name><surname>Nakaya</surname><given-names>S</given-names></name><name><surname>Kasper</surname><given-names>CK</given-names></name><name><surname>Thompson</surname><given-names>AR</given-names></name><name><surname>Almasy</surname><given-names>L</given-names></name><name><surname>Howard</surname><given-names>TE</given-names></name></person-group><article-title>Inhibitors of factor VIII in black patients with hemophilia</article-title><source>N Engl J Med 16</source><year>2009</year><volume>360</volume><fpage>1618</fpage><lpage>1627</lpage></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Mannucci</surname><given-names>PM</given-names></name><name><surname>Tuddenham</surname><given-names>EG</given-names></name></person-group><article-title>The hemophilias--from royal genes to gene therapy</article-title><source>N Engl J Med</source><year>2001</year><volume>344</volume><fpage>1773</fpage><lpage>1779</lpage><pub-id pub-id-type="pmid">11396445</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Fulcher</surname><given-names>CA</given-names></name><name><surname>de Graaf Mahoney</surname><given-names>S</given-names></name><name><surname>Zimmerman</surname><given-names>TS</given-names></name></person-group><article-title>FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting</article-title><source>Blood</source><year>1987</year><volume>69</volume><fpage>1475</fpage><lpage>1480</lpage><pub-id pub-id-type="pmid">2436689</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Hoyer</surname><given-names>LW</given-names></name></person-group><article-title>The factor VIII complex: structure and function</article-title><source>Blood</source><year>1981</year><volume>58</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">6165414</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>J</given-names></name><name><surname>Pavlova</surname><given-names>A</given-names></name></person-group><article-title>Genetic risk factors for inhibitors to factors VIII and IX</article-title><source>Haemoph Off J World Fed Hemoph</source><year>2006</year><volume>12(Suppl 6)</volume><fpage>15</fpage><lpage>22</lpage></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Witmer</surname><given-names>C</given-names></name><name><surname>Young</surname><given-names>G</given-names></name></person-group><article-title>Factor VIII inhibitors in hemophilia A: rationale and latest evidence</article-title><source>Ther Adv Hematol</source><year>2013</year><volume>4</volume><fpage>59</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">23610614</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Bardi</surname><given-names>E</given-names></name><name><surname>Astermark</surname><given-names>J</given-names></name></person-group><article-title>Genetic risk factors for inhibitors in haemophilia A</article-title><source>Eur J Haematol</source><year>2015</year><volume>94(Suppl 77)</volume><fpage>710</fpage></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Carcao</surname><given-names>M</given-names></name><name><surname>Re</surname><given-names>W</given-names></name><name><surname>Ewenstein</surname><given-names>B</given-names></name></person-group><article-title>The role of previously untreated patient studies in understanding the development of FVIII inhibitors</article-title><source>Haemoph Off J World Fed Hemoph</source><year>2016</year><volume>22</volume><fpage>22</fpage><lpage>31</lpage></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Gorski</surname><given-names>MM</given-names></name><name><surname>Blighe</surname><given-names>K</given-names></name><name><surname>Lotta</surname><given-names>LA</given-names></name><name><surname>Pappalardo</surname><given-names>E</given-names></name><name><surname>Garagiola</surname><given-names>I</given-names></name><name><surname>Mancini</surname><given-names>I</given-names></name><name><surname>Mancuso</surname><given-names>ME</given-names></name><name><surname>Fasulo</surname><given-names>MR</given-names></name><name><surname>Santagostino</surname><given-names>E</given-names></name><name><surname>Peyvandi</surname><given-names>F</given-names></name></person-group><article-title>Whole-exome sequencing to identify genetic risk variants underlying inhibitor development in severe hemophilia A patients</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>2924</fpage><lpage>2933</lpage><pub-id pub-id-type="pmid">27060170</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Palla</surname><given-names>R</given-names></name><name><surname>Garagiola</surname><given-names>I</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name><name><surname>Peyvandi</surname><given-names>F;</given-names></name></person-group><collab>SIPPET Study Group</collab><article-title>Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis</article-title><source>Blood</source><year>2017</year><volume>130</volume><fpage>1757</fpage><lpage>1759</lpage><pub-id pub-id-type="pmid">28768627</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Gouw</surname><given-names>SC</given-names></name><name><surname>van den Berg</surname><given-names>HM</given-names></name><name><surname>Oldenburg</surname><given-names>J</given-names></name><name><surname>Astermark</surname><given-names>J</given-names></name><name><surname>de Groot</surname><given-names>PG</given-names></name><name><surname>Margaglione</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>AR</given-names></name><name><surname>van Heerde</surname><given-names>W</given-names></name><name><surname>Boekhorst</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>CH</given-names></name><name><surname>le Cessie</surname><given-names>S</given-names></name><name><surname>van der Bom</surname><given-names>JG</given-names></name></person-group><article-title>F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>2922</fpage><lpage>2934</lpage><pub-id pub-id-type="pmid">22282501</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>AB</given-names></name><name><surname>Miller</surname><given-names>CH</given-names></name><name><surname>Kelly</surname><given-names>FM</given-names></name><name><surname>Michael Soucie</surname><given-names>J</given-names></name><name><surname>Craig Hooper</surname><given-names>W</given-names></name></person-group><article-title>The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource</article-title><source>Hum Mutat</source><year>2013</year><volume>34</volume><fpage>E2382</fpage><lpage>2391</lpage><pub-id pub-id-type="pmid">23280990</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Chenna</surname><given-names>R</given-names></name><name><surname>Sugawara</surname><given-names>H</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name><name><surname>Thompson</surname><given-names>JD</given-names></name></person-group><article-title>Multiple sequence alignment with the Clustal series of programs</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>3497</fpage><lpage>3500</lpage><pub-id pub-id-type="pmid">12824352</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><article-title>SIFT: Predicting amino acid changes that affect protein function</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>3812</fpage><lpage>3814</lpage><pub-id pub-id-type="pmid">12824425</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Sunyaev</surname><given-names>S</given-names></name><name><surname>Ramensky</surname><given-names>V</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name></person-group><article-title>Towards a structural basis of human non-synonymous single nucleotide polymorphisms</article-title><source>Trends Genet</source><year>2000</year><volume>16</volume><fpage>198</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">10782110</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Tavtigian</surname><given-names>SV</given-names></name><name><surname>Byrnes</surname><given-names>GB</given-names></name><name><surname>Goldgar</surname><given-names>DE</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name></person-group><article-title>Classification of rare missense substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications</article-title><source>Hum Mutat</source><year>2008</year><volume>29</volume><fpage>1342</fpage><lpage>1354</lpage><pub-id pub-id-type="pmid">18951461</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Luu</surname><given-names>TD</given-names></name><name><surname>Rusu</surname><given-names>A</given-names></name><name><surname>Walter</surname><given-names>V</given-names></name><name><surname>Linard</surname><given-names>B</given-names></name><name><surname>Poidevin</surname><given-names>L</given-names></name><name><surname>Ripp</surname><given-names>R</given-names></name><name><surname>Moulinier</surname><given-names>L</given-names></name><name><surname>Muller</surname><given-names>J</given-names></name><name><surname>Raffelsberger</surname><given-names>W</given-names></name><name><surname>Wicker</surname><given-names>N</given-names></name><name><surname>Lecompte</surname><given-names>O</given-names></name><name><surname>Thompson</surname><given-names>JD</given-names></name><name><surname>Poch</surname><given-names>O</given-names></name><name><surname>Nguyen</surname><given-names>H</given-names></name></person-group><article-title>KD4v: Comprehensible Knowledge Discovery System for Missense Variant</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><fpage>W71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">22641855</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>JM</given-names></name><name><surname>Rödelsperger</surname><given-names>C</given-names></name><name><surname>Schuelke</surname><given-names>M</given-names></name><name><surname>Seelow</surname><given-names>D</given-names></name></person-group><article-title>MutationTaster evaluates disease-causing potential of sequence alterations</article-title><source>Nat Methods</source><year>2010</year><volume>7</volume><fpage>575</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">20676075</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Hamasaki-Katagiri</surname><given-names>N</given-names></name><name><surname>Salari</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Schiller</surname><given-names>T</given-names></name><name><surname>Filiberto</surname><given-names>AC</given-names></name><name><surname>Schisterman</surname><given-names>EF</given-names></name><name><surname>Komar</surname><given-names>AA</given-names></name><name><surname>Przytycka</surname><given-names>TM</given-names></name><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name></person-group><article-title>A gene-specific method for predicting hemophilia-causing point mutations</article-title><source>J Mol Biol</source><year>2013</year><volume>425</volume><fpage>4023</fpage><lpage>4033</lpage><pub-id pub-id-type="pmid">23920358</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Doss</surname><given-names>CGP</given-names></name></person-group><article-title>In silico profiling of deleterious amino acid substitutions of potential pathological importance in haemophlia A and haemophlia B</article-title><source>J Biomed Sci</source><year>2012</year><volume>19</volume><fpage>30</fpage><pub-id pub-id-type="pmid">22423892</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>ML</given-names></name><name><surname>Shen</surname><given-names>BW</given-names></name><name><surname>Nakaya</surname><given-names>S</given-names></name><name><surname>Pratt</surname><given-names>KP</given-names></name><name><surname>Fujikawa</surname><given-names>K</given-names></name><name><surname>Davie</surname><given-names>EW</given-names></name><name><surname>Stoddard</surname><given-names>BL</given-names></name><name><surname>Thompson</surname><given-names>AR</given-names></name></person-group><article-title>Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure</article-title><source>Blood</source><year>2000</year><volume>96</volume><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="pmid">10910913</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>M</given-names></name><name><surname>Sarkar</surname><given-names>D</given-names></name><name><surname>Ganguly</surname><given-names>K</given-names></name><name><surname>Sengupta</surname><given-names>D</given-names></name><name><surname>Bhaskar</surname><given-names>S</given-names></name><name><surname>Ray</surname><given-names>K</given-names></name></person-group><article-title>In silico analyses of missense mutations in coagulation factor VIII: identification of severity determinants of haemophilia A</article-title><source>Haemoph Off J World Fed Hemoph</source><year>2015</year><volume>21</volume><fpage>662</fpage><lpage>669</lpage></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Bogdanova</surname><given-names>N</given-names></name><name><surname>Markoff</surname><given-names>A</given-names></name><name><surname>Eisert</surname><given-names>R</given-names></name><name><surname>Wermes</surname><given-names>C</given-names></name><name><surname>Pollmann</surname><given-names>H</given-names></name><name><surname>Todorova</surname><given-names>A</given-names></name><name><surname>Chlystun</surname><given-names>M</given-names></name><name><surname>Nowak-Göttl</surname><given-names>U</given-names></name><name><surname>Horst</surname><given-names>J</given-names></name></person-group><article-title>Spectrum of molecular defects and mutation detection rate in patients with mild and moderate hemophilia A</article-title><source>Hum Mutat</source><year>2007</year><volume>28</volume><fpage>54</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16972227</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Jayandharan</surname><given-names>G</given-names></name><name><surname>Shaji</surname><given-names>RV</given-names></name><name><surname>Baidya</surname><given-names>S</given-names></name><name><surname>Nair</surname><given-names>SC</given-names></name><name><surname>Chandy</surname><given-names>M</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name></person-group><article-title>Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions</article-title><source>Haemoph Off J World Fed Hemoph</source><year>2005</year><volume>11</volume><fpage>481</fpage><lpage>491</lpage></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Oldenburg</surname><given-names>J</given-names></name></person-group><article-title>Mutation profiling in haemophilia A</article-title><source>Thromb Haemost</source><year>2001</year><volume>85</volume><fpage>577</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">11341488</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Pipe</surname><given-names>SW</given-names></name></person-group><article-title>Functional roles of the factor VIII B domain</article-title><source>Haemoph Off J World Fed Hemoph</source><year>2009</year><volume>15</volume><fpage>1187</fpage><lpage>1196</lpage></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Ogata</surname><given-names>K</given-names></name><name><surname>Selvaraj</surname><given-names>SR</given-names></name><name><surname>Miao</surname><given-names>HZ</given-names></name><name><surname>Pipe</surname><given-names>SW</given-names></name></person-group><article-title>Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping</article-title><source>J Thromb Haemost</source><year>2011</year><volume>9</volume><fpage>1183</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">21645226</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Saenko</surname><given-names>EL</given-names></name><name><surname>Ananyeva</surname><given-names>NM</given-names></name><name><surname>Tuddenham</surname><given-names>EGD</given-names></name><name><surname>Kemball-Cook</surname><given-names>G</given-names></name></person-group><article-title>Factor VIII - novel insights into form and function</article-title><source>Br J Haematol</source><year>2002</year><volume>119</volume><fpage>323</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">12406064</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>AR</given-names></name></person-group><article-title>Structure and function of the factor VIII gene and protein</article-title><source>Semin Thromb Hemost</source><year>2003</year><volume>29</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">12640560</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Pittman</surname><given-names>DD</given-names></name><name><surname>Kaufman</surname><given-names>RJ</given-names></name></person-group><article-title>Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII)</article-title><source>Proc Natl Acad Sci U S A</source><year>1988</year><volume>85</volume><fpage>2429</fpage><lpage>2433</lpage><pub-id pub-id-type="pmid">3128786</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Butenas</surname><given-names>S</given-names></name><name><surname>van’t Veer</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>KG</given-names></name></person-group><article-title>“Normal” thrombin generation</article-title><source>Blood</source><year>1999</year><volume>94</volume><fpage>21692178</fpage></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>McMullen</surname><given-names>BA</given-names></name><name><surname>Fujikawa</surname><given-names>K</given-names></name><name><surname>Davie</surname><given-names>EW</given-names></name><name><surname>Hedner</surname><given-names>U</given-names></name><name><surname>Ezban</surname><given-names>M</given-names></name></person-group><article-title>Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)</article-title><source>Protein Sci Publ Protein Soc</source><year>1995</year><volume>4</volume><fpage>740</fpage><lpage>746</lpage></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Gouw</surname><given-names>SC</given-names></name><name><surname>van der Bom</surname><given-names>JG</given-names></name><name><surname>Ljung</surname><given-names>R</given-names></name><name><surname>Escuriola</surname><given-names>C</given-names></name><name><surname>Cid</surname><given-names>AR</given-names></name><name><surname>Claeyssens-Donadel</surname><given-names>S</given-names></name><name><surname>van Geet</surname><given-names>C</given-names></name><name><surname>Kenet</surname><given-names>G</given-names></name><name><surname>Mäkipernaa</surname><given-names>A</given-names></name><name><surname>Molinari</surname><given-names>AC</given-names></name><name><surname>Muntean</surname><given-names>W</given-names></name><name><surname>Kobelt</surname><given-names>R</given-names></name><name><surname>Rivard</surname><given-names>G</given-names></name><name><surname>Santagostino</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>van den Berg</surname><given-names>HM;</given-names></name></person-group><collab>PedNet and RODIN Study Group</collab><article-title>Factor VIII products and inhibitor development in severe hemophilia A</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>231</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">23323899</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Spena</surname><given-names>S</given-names></name><name><surname>Garagiola</surname><given-names>I</given-names></name><name><surname>Cannavò</surname><given-names>A</given-names></name><name><surname>Mortarino</surname><given-names>M</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name><name><surname>Rosendaal</surname><given-names>FR</given-names></name><name><surname>Peyvandi</surname><given-names>F;</given-names></name></person-group><collab>SIPPET Study Group</collab><article-title>Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement</article-title><source>J Thromb Haemost</source><year>2018</year><volume>16</volume><fpage>778</fpage><lpage>790</lpage><pub-id pub-id-type="pmid">29399993</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Schwaab</surname><given-names>R</given-names></name><name><surname>Pavlova</surname><given-names>A</given-names></name><name><surname>Albert</surname><given-names>T</given-names></name><name><surname>Caspers</surname><given-names>M</given-names></name><name><surname>Oldenburg</surname><given-names>J</given-names></name></person-group><article-title>Significance of F8 missense mutations with respect to inhibitor formation</article-title><source>Thromb Haemost</source><year>2013</year><volume>109</volume><fpage>464</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">23306409</pub-id></element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal" publication-format="online"><person-group person-group-type="author"><name><surname>Chaves</surname><given-names>DG</given-names></name><name><surname>Velloso-Rodrigues</surname><given-names>C</given-names></name><name><surname>Moreau</surname><given-names>V</given-names></name><name><surname>Nguyen</surname><given-names>C</given-names></name><name><surname>Villard</surname><given-names>S</given-names></name><name><surname>Belisário</surname><given-names>AR</given-names></name><name><surname>Granier</surname><given-names>C</given-names></name><name><surname>Santoro</surname><given-names>MM</given-names></name></person-group><article-title>Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains</article-title><source>Br J Haematol</source><year>2008</year><volume>141</volume><fpage>708</fpage><lpage>715</lpage><pub-id pub-id-type="pmid">18422780</pub-id></element-citation></ref></ref-list></back><floats-group><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Prediction results of studied variations’ effects on the protein function and/or structure.</title></caption><graphic xlink:href="TJH-37-77-g1"></graphic></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Distribution of single-nucleotide polymorphisms in patients with or without inhibitors.</title></caption><graphic xlink:href="TJH-37-77-g2"></graphic></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Variation distribution in the patients that developed inhibitors according to the change of amino acidic class. 1: Hydrophobic (A, V, L, I, M, P, F). 2: Polar uncharged (S, Y, N, Q, C, T, H, G). 3: Acidic (D, E). 4: Basic (K, R).</title></caption><graphic xlink:href="TJH-37-77-g3"></graphic></table-wrap><fig id="f1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Variation distribution according to the A and C domains.</p></caption><graphic xlink:href="TJH-37-77-g4"></graphic></fig><fig id="f2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Deleterious and neutral variation distribution according to the A and C domains. ***: p<0.001.</p></caption><graphic xlink:href="TJH-37-77-g5"></graphic></fig><fig id="f3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Correlation between variation character (deleterious/neutral) and inhibitor formation.</p></caption><graphic xlink:href="TJH-37-77-g6"></graphic></fig><fig id="f4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Correlation of variation localization on each domain with inhibitor formation.</p></caption><graphic xlink:href="TJH-37-77-g7"></graphic></fig></floats-group></pmc>
